Haemonetics (HAE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Transformation progress and recent performance

• Completed a four-year long-range plan, surpassing growth and earnings targets, with 10% revenue growth and mid-20% earnings growth, though margin expansion reached 25% instead of the high 20%s goal.

• Achieved over $650 million in free cash flow and implemented sustainable operational improvements, including portfolio evolution, capability building, and a major ERP investment.

• Most initiatives from the transformation are expected to provide ongoing benefits.

FY 2027 guidance and operational outlook

• Issued conservative FY 2027 guidance of 3%-6% organic growth, reflecting market uncertainties and a focus on factors within direct control.

• Key growth drivers include share gains, innovation rollouts like Persona PLUS, and modest collection/procedure rate increases.

• Margin expansion of 50-100 basis points expected, primarily from operating leverage in med-surg businesses.

• Upside to guidance could come from faster adoption of new technologies, higher collection volumes, and continued share gains.

Market and sector dynamics

• Healthy procedure and collection volumes observed across core markets, with robust demand in plasma, cardiology, and trauma segments.

• Sector faces macroeconomic and competitive pressures, but underlying demand for plasma and blood management remains strong.

• Adoption of advanced technologies and stabilization in access site growth expected to support future growth.